Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Serum prostate-specific antigen (PSA) level is the most valuable biomarker in prostate cancer. This study investigates the predictive value of achieving >30% PSA decline at four weeks of first-line androgen signaling inhibitors (ASIs) using a multi-institutional cohort dataset of...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchimoto, Taizo, Komura, Kazumasa, Fukuokaya, Wataru, Kimura, Takahiro, Takahashi, Kazuhiro, Nishimura, Kazuki, Nakamori, Keita, Fujiwara, Yuya, Matsunaga, Tomohisa, Tsutsumi, Takeshi, Tsujino, Takuya, Maenosono, Ryoichi, Yoshikawa, Yuki, Taniguchi, Kohei, Tanaka, Tomohito, Uehara, Hirofumi, Ibuki, Naokazu, Hirano, Hajime, Nomi, Hayahito, Takahara, Kiyoshi, Inamoto, Teruo, Egawa, Shin, Azuma, Haruhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866532/
https://www.ncbi.nlm.nih.gov/pubmed/33573172
http://dx.doi.org/10.3390/cancers13030526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866532/
https://www.ncbi.nlm.nih.gov/pubmed/33573172
http://dx.doi.org/10.3390/cancers13030526

Ejemplares similares